Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
29.89
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna, Inc. - Common Stock
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
June 07, 2024
Via
ACCESSWIRE
5 Stocks Propelling S&P 500 To 25th Record High
↗
June 06, 2024
While most of the stocks have performed well, here are five of them that led the way higher in yesterday's trading session.
Via
Talk Markets
Topics
Stocks
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
↗
June 06, 2024
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.
Via
Benzinga
Novavax Stock’s Recent Surge and Future Potential
June 06, 2024
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance.
Via
MarketBeat
Topics
Economy
If You Invested $100 In This Stock 5 Years Ago, You Would Have $800 Today
↗
June 03, 2024
Via
Benzinga
Breaking Down Moderna: 7 Analysts Share Their Views
↗
June 03, 2024
Via
Benzinga
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
↗
June 06, 2024
Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study.
Via
Benzinga
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
↗
June 06, 2024
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze.
Via
InvestorPlace
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
↗
June 06, 2024
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall.
Via
Investor's Business Daily
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
June 06, 2024
Via
ACCESSWIRE
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024
Via
ACCESSWIRE
Why Moderna Stock Is Sinking This Week
↗
May 30, 2024
Moderna's sell-off this week is for the birds.
Via
The Motley Fool
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
↗
June 05, 2024
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off.
Via
InvestorPlace
Why Is Novavax (NVAX) Stock Up 20% Today?
↗
June 05, 2024
Novavax continues to march higher in its recovery efforts, with its latest vaccine announcement lifting NVAX stock.
Via
InvestorPlace
S&P 500, Nasdaq 100 Jointly Hit All-Time Highs, Nvidia Overtakes Apple As Second Most Valuable US Company
↗
June 05, 2024
The S&P 500 and Nasdaq 100 indices closed at record highs due to investor confidence in AI-driven tech sector growth. Magnificent Seven worth $15T.
Via
Benzinga
Topics
Stocks
What's Going On With Novavax Stock?
↗
June 05, 2024
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on.
Via
Benzinga
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
↗
June 04, 2024
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co...
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
↗
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
↗
June 03, 2024
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3...
Via
Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
June 03, 2024
Via
ACCESSWIRE
Is Moderna Stock a Buy Now That It's a 2-Product Company?
↗
June 03, 2024
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.
Via
The Motley Fool
Moderna Investors Just Got Some Bullish News
↗
June 03, 2024
This news could be worth billions...
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
May 31, 2024
Via
Benzinga
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
↗
May 31, 2024
FDA approves Moderna's mRESVIA (mRNA-1345), an mRNA vaccine for RSV, for adults 60+. The second approved mRNA product from Moderna.
Via
Benzinga
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
↗
May 31, 2024
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years.
Via
Investor's Business Daily
3 Sorry Biotech Stocks to Sell in May While You Still Can
↗
May 31, 2024
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell.
Via
InvestorPlace
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
May 30, 2024
Via
AB Newswire
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
